All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Blinatumomab + ponatinib in patients with newly diagnosed Ph+ ALL: Phase II findings
Bookmark this article
|
Blinatumomab + ponatinib has the potential to offer a chemotherapy-free regimen in patients with Ph+ ALL. Results from a phase II trial evaluating the efficacy and safety of the combination in 76 patients with ND Ph+ ALL were presented by Nicholas Short at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
|
Blinatumomab + ponatinib produced a CR/CRi rate in 98% of patients, a CMR-negative status in 83%, and a NGS MRD-negative status in 96%. |
| At a median follow-up of 29 months, the 3-year RFS and OS were 78% and 88%, respectively. MVA showed that WBC ≥70,000 vs ≤70,000 was associated with relapse, with a CIR of 52% vs 6% (p < 0.001). |
| Relapse and death in patients with a CR were reported in 13.2% and 4.0% of patients, respectively, while 3.0% of patients received transplantation. |
| The results show that the blinatumomab + ponatinib achieved deep and durable responses in patients with ND Ph+ ALL. However, novel strategies are needed for patients with high-risk Ph+ ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; CIR, cumulative incidence of relapse; CMR, complete molecular remission; CR, complete remission; CRi, CR with incomplete hematologic recovery; MVA, multivariate analysis; ND, newly diagnosed; NGS, next-generation sequencing; MRD, measurable residual disease; OS, overall survival; Ph+, Philadelphia chromosome-positive; RFS, relapse-free survival; WBC, white blood cell.
- 1. Short N. Oral abstract #837. Blinatumomab and ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results and predictors of relapse. Presented at: 66th ASH Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
14 votes - 22 days left ...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox